(NASDAQ: SOPA) Profile
OUR NEW PROFILE IS: (NASDAQ: SOPA) WITH CASH ON HAND OF $8.2 MILLION (APPROXIMATELY $0.26 PER SHARE) AND BOOK VALUE OF $9.9 MILLION(APPROXIMATELY $0.32 PER SHARE) AS OF 30 SEPTEMBER 2023, SOPA IS WELL CAPITALISED FOR CONTINUING ACQUISITIONS OF SEA COMPANIES IN ITS DIGITAL ADVERTISING, TRAVEL, LIFESTYLE, TELECOMMUNICATIONS, AND LOYALTY/FINTECH VERTICALS FOR THE REST OF 2023 AND 2024 SOPA JUST ANNOUNCEED THAT […]
(Nasdaq: GDC) Profile
OUR NEW PROFILE IS: (NASDAQ: GDC) ____________________ GD CULTURE GROUP EXPANDS INTO LIVESTREAMING INTERACTIVE GAMES ON TIKTOK GDC HAS BEEN ON A SLOW AND STEADY MOVE NORTH THROUGHOUT 2023 __________________________________________ Hello Everyone, We have another profile for you to look at and research before the open on Monday morning. Pull up GDC. This is another […]
(Nasdaq: SXTP) Profile
OUR NEW PROFILE IS: (NASDAQ: SXTP) ____________________ SXTP HAS JUST 5 MILLION SHARES IN THE FLOAT ACCORDING TO FINVIZ SXTP PIVOTS TO REFOCUS ON COMMERCIALIZATION OF TREATMENTS FOR MALARIA AND TICK-BORNE DISEASES READ THE INVESTOR PRESENTATION HERE __________________________________________ Hello Everyone, I hope that you are paying attention. We sent out our last profile at 2 pm […]
(Nasdaq: NNVC) Profile
OUR NEW PROFILE IS: (NYSE AMERICAN: NNVC) NV-387 IS HIGHLY ACTIVE AGAINST TESTED CORONAVIRUSES INCLUDING SARS-COV-2 IN PRE-CLINICAL STUDIES THE ENTIRE FLOAT ON NNVC IS JUST 11.2 MILL ACCORDING TO FINVIZ!!!! READ THE INVESTOR PRESENTATION HERE ______________________________________________________________ Hello Everyone, We have another new profile that we want you to research right away. This is one you should […]
(NYSE American: MAIA) Profile
OUR NEW PROFILE IS: (NYSE AMERICAN: MAIA) MAIA BIOTECHNOLOGY RECENTLY ANNOUNCES SHARE REPURCHASE PROGRAM MAIA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR THIO, A FIRST-IN-CLASS TELOMERE TARGETING AGENT FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA READ THE INVESTOR […]
(Nasdaq: IVP) Profile
OUR NEW PROFILE IS: (NASDAQ: IVP) ____________________ REVENUE RUN RATE ~$19M, 13LOCATIONS ACROSS 9 STATES, ~$3.5M IN REI 3 NEW LOCATIONS UNDER LOI WHICH WILL BRING AN ADDITION $6M OF ANNUAL REVENUE AND $2M IN REI IN THE LAST 2 MONTHS THE COMPANY HAS PROPOSED ACQUISITIONS TO ADD 3 NEW ANIMAL HOSPITALS TO THEIR CURRENT […]
BSGM Nasdaq Profile
_______ OUR NEW PROFILE IS: (NASDAQ: BSGM) BIOSIG’S NEW PURE EP™ SUBSCRIPTION MODEL ADOPTED BY MAYO CLINIC-PHOENIX FOR WORLD-CLASS CARDIAC CARE OVER 3,000 PROCEDURES HAVE BEEN PERFORMED USING THE PURE EP™ SYSTEM WITH MORE THAN 80 PHYSICIANS AT 21 HOSPITALS ACROSS THE UNITED STATES SUBSTANTIAL AND GROWING IP PATENT PORTFOLIO IN 2022 THE CEO PURCHASED […]
(NASDAQ: WLDS) Profile
OUR NEW PROFILE IS: (NASDAQ: WLDS) THE ENTIRE FLOAT IS UNDER 8 MILL RIGHT NOW!!! Wearable Devices Unveils New Gesture & Voice-Controlled Interface for its Mudra Band for Apple Watch Wearable Devices Expands Mudra Licensing Program to Include Defense and Military Applications Wearable Devices Entered an MOU with a Leading XR Smart Glasses OEM for its […]
(NASDAQ: SVRE) Profile
OUR NEW PROFILE IS: (NASDAQ: SVRE) ~4,300 SYSTEMS HAVE BEEN ORDERED BY CUSTOMERS ~4X (286%) YEAR-OVER-YEAR GROWTH IN REVENUE T0 $399K IN THE FIRST HALF OF 2023 ~SAVERONE SYSTEM INSTALLED ON 30 DELIVERY TRUCKS OF TEMPO BEVERAGES- ISRAEL’S LEADING BEVERAGE COMPANY READ THE INVESTOR PRESENTATION HERE _________________ Hello Everyone, We have another Nasdaq profile sitting […]
(Nasdaq: NMTC) Profile
OUR NEW PROFILE IS: (NASDAQ: NMTC) STRATEGIC PARTNERSHIP WITH ZIMMER BIOMET (NYSE:ZBH, ~$27B MKT CAP) TO EXCLUSIVELY COMMERCIALIZE AND DISTRIBUTE EVO® DIAGNOSTIC ELECTRODES; ACCELERATED PAYMENT OF $3.5 MILLION RECEIVED IN AUGUST 2022 NMTC HAS NO DEBT OUTSTANDING AS OF JUNE 30, 2023 NEUROONE® SUCCESSFULLY COMPLETES INITIAL ANIMAL IMPLANT OF NOVEL THIN FILM PADDLE LEAD FOR […]